MedicoInsights’ Post

News! Alembic Pharmaceuticals Limited Receives US FDA Approval for Sacubitril and Valsartan Tablets: 📍Company: Alembic Pharmaceuticals Limited. 📍Approval: Received final approval from the US FDA. 📍Drug: Sacubitril and Valsartan tablets. 📍Equivalent to: Entresto Tablets by Novartis Pharmaceuticals. 💊Uses: - Reduces the risk of cardiovascular death and hospitalizations for heart failure in adults with chronic heart failure. - Treats symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. 💪Market Size: Estimated at $5.3 billion for the twelve months ending March 2024, according to IQVIA. #alembic #novartis #sacubitril #valsartan #heart #cardiovasculardiseases #iqvia #usfda

Orforglipron: the new kid on the GLP-1 block Orforglipron was originally discovered and developed by Chugai Pharmaceutical Co., Ltd. Eli Lilly licensed the worldwide development and commercialisation rights for Orforglipron from Chugai in 2018. Eli Lilly is currently running the clinical trials (phase 3) to see if Orforglipron is effective and safe for weight management and type 2 diabetes treatment. If successful, Eli Lilly would be responsible for bringing the drug to market. Type of drug: It's a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone that helps regulate blood sugar and appetite. Function: Orforglipron works by mimicking the effects of GLP-1, which can increase insulin production, slow digestion, and promote feelings of fullness, ultimately leading to weight loss and improved blood sugar control. Benefits: If approved, orforglipron could offer a convenient once-daily oral medication for weight management and type 2 diabetes compared to injectable GLP-1 drugs currently available. It's also expected to be cheaper to produce. Stage of development: Orforglipron is currently in phase 3 clinical trials, which are large-scale studies to assess its efficacy and safety before it can be submitted for regulatory approval. Side effects: Like other GLP-1 drugs, Orforglipron may cause gastrointestinal side effects, which are usually mild to moderate and tend to happen during the initial dose increase. Mergers, Acquisitions, Growth and Strategy for Healthcare Technology companies HealthTech M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb Healthcare Technology Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://lnkd.in/ezyUh5i https://lnkd.in/dJG_G42J #HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

Dapagliflozin, developed by Parand Darou pharmaceutical company as an SGLT2 inhibitor, is a treatment for individuals with type 2 diabetes. By blocking SGLT2 cotransporters responsible for glucose reabsorption in the kidneys, this medication enhances glucose excretion, leading to reduced blood glucose levels. However, the standout feature of dapagliflozin lies in its additional benefits for heart failure and kidney complications in diabetic patients. Specifically recommended for diabetic individuals with existing or at-risk cardiovascular issues, this drug also helps lower cardiovascular risks and is an integral part of their treatment regimen. Parand Darou #diabetes #pharmaceutical #medicine #api #pharma #paranddarou

Alembic Pharma gets USFDA nod to Diltiazem Hydrochloride ER Capsules to treat hypertension Drug maker Alembic Pharmaceuticals Limited has recently announced that it has received final approval from the United States Food and Drug Administration (US FDA) for the abbreviated new drug application (ANDA) Diltiazem Hydrochloride extended-release capsules of strengths 120 mg, 180 mg, and 240 mg. The approved ANDA is therapeutically equivalent to the reference listed drug, Dilacor XR Extended-Release Capsules (120 mg, 180 mg, and 240 mg), manufactured by Allergan Sales LLC, the company said in a statement. Diltiazem Hydrochloride Extended-Release Capsules USP are prescribed for hypertension management and can be used alone or alongside other antihypertensive drugs, like diuretics. Additionally, they are indicated for managing chronic stable angina. #AlembicPharma #USFDA #ANDA #DilacorXRExtendedReleaseCapsules #AllerganSalesLLC #DiltiazemHydrochlorideExtendedReleaseCapsules

Sun Pharma to introduce gastrointestinal drugs in India Day #92 of covering Pharma Developments. 💊News Buzz.!! Sun Pharma has entered into a non exclusive patent licensing agreement with Takeda Pharmaceutical Company to commercialise Voltapraz. 💊What is Voltapraz.? Voltapraz is a brand name for the medication Vonoprazan, a prescription drug used to treat acid-related stomach disorders 💊Who developed Voltapraz.? Discovered and developed by Takeda, Vonoprazan is a novel, orally active potassium competitive acid blocker, used to treat reflux esophagitis and other acid peptic disorders. 💊When did USFDA approve this.? The drug was approved by USFDA on Nov 2023. I will provide the source of the article in the comment section below. By the way today is the 92nd day of me deep diving into the pharmaceutical industry. I will be sharing insights from this industry on a regular basis. So please do follow me (Krishna Raj K) for such insights. #Finance #Linkedin #India

Today, Idorsia Pharmaceuticals Ltd announced the FDA approval of TRYVIO (aprocitentan), marking it the first and only endothelin receptor antagonist for the treatment of hypertension in combination with other antihypertensive drugs to reduce blood pressure in adult patients who are inadequately controlled on other therapies.   This approval is based on the Phase 3 multicenter study evaluating the efficacy of TRYVIO in adults with systolic blood pressure (SBP) ≥140 mmHg who were on at least three antihypertensive medications. The study showed that TRYVIO 12.5 mg significantly reduced SBP compared to placebo at Week 4, and its blood pressure-lowering effect persisted throughout the trial. Read More: https://lnkd.in/eWAEHrTr   #FDAApproval #Hypertension #Idorsia #TRYVIO 

💊 Teva Pharmaceuticals has announced the launch of an authorized generic version of Victoza (liraglutide, 1.8 mg injection) in the United States — a significant development in the diabetes management. This move could have substantial implications for patients, healthcare providers, and the broader healthcare system. Liraglutide, Victoza's active ingredient, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood sugar control in adults with type 2 diabetes. By mimicking the action of the naturally occurring hormone GLP-1, it helps stimulate insulin secretion and slow glucose absorption, effectively managing blood sugar levels. Since its approval in January 2010, Victoza has been a critical component of diabetes care, offering significant clinical benefits. The introduction of this authorized generic version by Teva is poised to make this vital medication more accessible. Authorized generics are identical to brand-name drugs in dosage, safety, strength, quality, and performance characteristics. They are typically sold at a lower cost than the brand-name counterpart, offering a cost-effective alternative for patients and the healthcare system. #Teva #Victoza #GenericMedication #PharmaNews #Healthcare #AffordableMedicine #DiabetesCare #HealthNews #Medication #Pharmaceuticals

The US FDA has given the green light to adalimumab-ryvk (Simlandi), the first interchangeable, high-concentration, citrate-free adalimumab biosimilar. This marks a significant milestone as the 10th adalimumab biosimilar approved by the FDA and the inaugural approval for Alvotech, an Icelandic pharmaceutical company, in collaboration with Teva Pharmaceuticals. Robert Wessman, Chairman and CEO of Alvotech, highlighted the potential market impact of this interchangeable, citrate-free biosimilar in the evolving U.S. biosimilars environment. Adalimumab-ryvk, previously approved in the EU, Australia, and Canada, is indicated for various conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Notably, it is the third Humira biosimilar granted interchangeability status, allowing pharmacists (subject to state law) to substitute it for the reference product without involving the prescribing clinician. This distinguishes it from other biosimilars, which are only interchangeable with the low-concentration formulation of Humira. The imminent launch of Adalimumab-ryvk in the U.S. is eagerly awaited, with details on pricing yet to be disclosed. The biosimilar market continues to evolve, offering new options and potential cost savings for patients. Stay tuned for further updates! LINK:https://lnkd.in/eaxnuMdF #FDAApproval #Biosimilars #HealthcareInnovation

Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/fM0k50RRFa6 #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies

https://lnkd.in/g4dT_xg7 Key Insights: • Doxazosin tablets are prescribed for hypertension treatment, aimed at reducing blood pressure • The product will be available for commercial distribution from UniChem’s manufacturing facility located in Goa Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #unichem #approval #fdaapproval #bloodpressure #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights